The research indicated upregulation of TCF7L2 inhibited the promoter activity of Egl-9 family hypoxia-inducible factor 2 (EGLN2) and suppressed its expression, which enhanced the stability of HIF-1α, enhancing glycolysis-related genes expression and increasing glycolysis in pancreatic cancer cells [37]. This evidence concerns the gene EGLN2 and pancreatic neoplasm.